Navigation Links
Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology

NATICK, Mass., June 04, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed the publication of an article in the Journal of of Cardiology (JACC) reviewing the TAXUS ATLAS clinical trial, which evaluates the Company's second-generation TAXUS(R) Liberte(TM)(1) paclitaxel-eluting stent system. The article in the April 24 edition of JACC concluded that the shorter procedure time and lower bailout rate of the TAXUS Liberte Stent system compared to the TAXUS(R) Express2(TM) Stent system may represent a clinical surrogate for the improved deliverability and conformability of the TAXUS Liberte Stent as compared to the TAXUS Express Stent.

TAXUS ATLAS is a global, multi-center single arm trial comparing the TAXUS Liberte paclitaxel-eluting stent system to a case-matched control group of patients from the TAXUS IV and TAXUS V de novo studies that received the TAXUS Express2 paclitaxel-eluting stent system. Even with more complex lesion characteristics(2) compared to the control group, the TAXUS ATLAS trial met its primary endpoint of nine-month target vessel revascularization (TVR) non-inferiority.

The TAXUS ATLAS nine-month results also support safety, as demonstrated by low rates of Major Adverse Cardiac Events (MACE) and stent thrombosis. The MACE rate and its components, including cardiac death, myocardial infarction and TVR, were comparable to control despite the higher percentage of complex lesions for the TAXUS Liberte Stent arm. Cardiac death for the control group was 0.9 percent compared to 0.8 percent for the TAXUS Liberte Stent (p=1.00). Myocardial infarction was 3.9 percent for the control group compared to 3.7 percent for the TAXUS Liberte Stent (p=0.9030). The nine-month TVR rate for the control group was 7.1 percent compared to 8.0 percent for the TAXUS Liberte Stent (p=0.4787). Similar TVR rates of 9.2 percent for the TAXUS Liberte Stent group, as compared to 8.9 perc
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:7/30/2014)... , July 30, 2014 Stryker brand ambassadors ... week at the 3M Championship Champions Tour event near ... in Blaine . Stryker is the official joint ... Starting Friday, August 1 st through Sunday, August ... Mobility Zone; an on-site joint health destination located in the Pioneer ...
(Date:7/30/2014)... , July 30, 2014 Silicon Valley Bank, ... a study today that examines the merger, acquisition ... device companies.  According to the annual report based on ... potential returns since SVB started tracking the data in ... IPO.  Built on solid healthcare M&A activity over the ...
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3
... the global leader in technology support and BPO services ... today the opening of its new Global Operations Center ... city of Dalian, will specialize in providing services in ... sponsors and clinical research organizations. With dramatic ...
... ARBOR, Mich., April 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: ... serious central nervous system diseases, announced today that it has ... its common stock at approximately $2.0725 per share to a ... million in gross proceeds. The investor will also receive warrants ...
Cached Medicine Technology:C3i Opens Asia Language Center in Dalian, China 2Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3
(Date:7/30/2014)... The Europe commercial aviation actuation system ... it is expected to reach $1,686.72 million by 2019 ... offers an exclusive range of opportunities and challenges which ... aviation has seen slumps in the past, yet the ... returned to its long-term growth rate of approximately 5 ...
(Date:7/30/2014)... 30, 2014 A marketing services ... technology startups is now available from Modern ... based in the Chicago region. The practice will ... information technology (IT), services, ecommerce, healthcare, private equity ... disciplines critical to startup success include competitive research, ...
(Date:7/30/2014)... Beach, CA (PRWEB) July 30, 2014 ... hired new employees and continues to grow quickly. Chris’ ... Suite 260, Laguna Beach, across the street from Three ... intersection. , Previous to State Farm, Chris had ... Restaurant industry headquartered in Irvine, California, where his responsibilities ...
(Date:7/30/2014)... Recently, Agebc.com, one of the most ... its new line of affordable flower girl dresses ... in several popular styles: sequined ball-gown, scoop neckline, fully ... company’s fresh assortment are: short chiffon dresses with delicate ... of course the classic beautiful colored tulle flower girl ...
(Date:7/30/2014)... teen who died of a caffeine overdose in May ... mass-consumed substance. To help prevent serious health problems that ... reporting progress toward a rapid, at-home test to detect ... and even breast milk. Their report appears in ACS, ... Mani Subramanian and colleagues note that caffeine,s popularity as ...
Breaking Medicine News(10 mins):Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 4Health News:Startup Marketing Practice Launched by Modern Marketing Partners 2Health News:State Farm Agent Chris Risi Is Celebrating His Agency's 1st Year Anniversary In September 2Health News:Affordable Flower Girl Dresses Recently Unveiled at Agebc.com 2
... danger, study warns , MONDAY, June 1 (HealthDay News) ... eat enough to cover their energy output face the ... female athletes in the same circumstances, new research suggests. ... place dancers at higher risk for the "cardiovascular ...
... OTTAWA, June 1 /PRNewswire-FirstCall/ - MDS Nordion, a leading ... of,Canada and Atomic Energy of Canada Limited (AECL) to ... the MAPLE,project to address the current shortage of medical ... (NRU) reactor at Chalk River,Ontario - and to avoid ...
... EMERYVILLE, Calif., June 1 Bayer HealthCare Pharmaceuticals, Inc. ... today announced that the companies have begun enrolling patients ... (sorafenib) tablets in patients with non-squamous non-small cell lung ... treatments. , , "Nexavar has proven efficacy in ...
... Expands Veran,s electromagnetic (EM) navigation for oncology procedures. ... Veran Medical Technologies announced today that it has ... property. Veran secured a worldwide license to ... The Navigation division of Medtronic has developed ...
... twenty-somethings who attend or have graduated from private religious ... peers from public schools, according to sociological research published ... Health and Social Behavior . "This research suggests ... of social, financial and health-related factors that can make ...
... International (NYSE: VRX ) announced today that it ... SGP ) for taribavirin in Japan. In ... and release its last right of refusal on taribavirin under ... pursue partnering arrangements for the rest of the world. ...
Cached Medicine News:Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 2Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 3Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 4Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 5Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 2Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 3Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 4Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 5Health News:Veran Medical Technologies Announces Intellectual Property Agreement With Medtronic 2Health News:Religious devotion does not impact abortion decisions of young unwed women 2Health News:Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 2Health News:Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 3
... technology makes BURANE XL a ... array of aesthetic laser applications. ... controllable mode for coagulation, an ... procedures, and in particular a ...
... Test is an in vitro immunoassay intended for ... tumor associated antigen. It is indicated for use ... cancer in conjunction with cystoscopy or when prescribed ... by the FDA for prescription home use in ...
Used for measuring rectal pressure during urodynamic studies. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open pack...
Used for cystometry and urethral pressure profilometry. A loop is employed to enhance catheter retention and stabilization within the bladder. Supplied sterile in peel-open packages. Intended for one...
Medicine Products: